

**1 Predictive validity of the simplified Radiographic Assessment of Lung Edema score for**  
**2 the mortality in critically ill COVID-19 patients with the B.1.617.2 (Delta) variant in**  
**3 Vietnam: a single-centre, cross-sectional study**

4 Son Ngoc Do<sup>1,2,3</sup>, Tuan Quoc Dang<sup>1,2</sup>, Chinh Quoc Luong<sup>2,3,4</sup>, My Ha Nguyen<sup>5</sup>, Dung Thi  
 5 Pham<sup>6</sup>, Viet Khoi Nguyen<sup>7,8</sup>, Tan Dang Do<sup>7</sup>, Thai Quoc Nguyen<sup>9</sup>, Vuong Minh Nong<sup>9</sup>, Khoi  
 6 Hong Vo<sup>10,11,12</sup>, Tan Cong Nguyen<sup>1,2,3</sup>, Nhung Hong Khuat<sup>2,13</sup>, Quynh Thi Pham<sup>2,14</sup>, Dat Tien  
 7 Hoang<sup>1,2</sup>, Anh Diep Nguyen<sup>2,15</sup>, Phuong Minh Nguyen<sup>2,16</sup>, Duong Dai Cao<sup>2,17</sup>, Dung Thuy  
 8 Pham<sup>2,18</sup>, Dung Tuan Dang<sup>4</sup>, Dat Tuan Nguyen<sup>2,3,4</sup>, Vinh Duc Nguyen<sup>4</sup>, Thuan Quang Le<sup>2,3,19</sup>,  
 9 Hung Duc Ngo<sup>2,4</sup>, Dung Van Nguyen<sup>9</sup>, Thach The Pham<sup>1,2,3</sup>, Dung Tien Nguyen<sup>2,19</sup>, Nguyen  
 10 Trung Nguyen<sup>2,3,19</sup>, Nhung Thi Huynh<sup>20</sup>, Nga Thu Phan<sup>5</sup>, Cuong Duy Nguyen<sup>21</sup>, Thom Thi  
 11 Vu<sup>22</sup>, Cuong Duy Do<sup>9,23</sup>, Chi Van Nguyen<sup>2,4</sup>, Giap Van Vu<sup>24,25</sup>, Co Xuan Dao<sup>1,2,3\*</sup>

12 <sup>1</sup> Center for Critical Care Medicine, Bach Mai Hospital, Hanoi, Vietnam

13 <sup>2</sup> Department of Emergency and Critical Care Medicine, Hanoi Medical University, Hanoi,  
 14 Vietnam

15 <sup>3</sup> Department of Emergency and Critical Care Medicine, Faculty of Medicine, University of  
 16 Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam

17 <sup>4</sup> Center for Emergency Medicine, Bach Mai Hospital, Hanoi, Vietnam

18 <sup>5</sup> Department of Health Organization and Management, Faculty of Public Health, Thai Binh  
 19 University of Medicine and Pharmacy, Thai Binh, Vietnam

20 <sup>6</sup> Department of Nutrition and Food Safety, Faculty of Public Health, Thai Binh University of  
 21 Medicine and Pharmacy, Thai Binh, Vietnam

22 <sup>7</sup> Radiology Centre, Bach Mai Hospital, Hanoi, Vietnam

23 <sup>8</sup> Department of Radiology, Hanoi Medical University, Hanoi, Vietnam

24 <sup>9</sup> Center for Tropical Diseases, Bach Mai Hospital, Hanoi, Vietnam

25 <sup>10</sup> Department of Neuro Intensive Care and Emergency Neurology, Neurology Center, Bach  
26 Mai Hospital, Hanoi, Vietnam

27 <sup>11</sup> Department of Neurology, Hanoi Medical University, Hanoi, Vietnam

28 <sup>12</sup> Department of Neurology, Faculty of Medicine, University of Medicine and Pharmacy,  
29 Vietnam National University, Hanoi, Vietnam

30 <sup>13</sup> Department of Intensive Care and Poison Control, Duc Giang General Hospital, Hanoi,  
31 Vietnam

32 <sup>14</sup> Intensive Care Unit, University Medical Center Ho Chi Minh City, University of Medicine  
33 and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam

34 <sup>15</sup> Intensive Care Unit, Hanoi Heart Hospital, Hanoi, Vietnam

35 <sup>16</sup> Intensive Care Unit, Thanh Nhan General Hospital, Hanoi, Vietnam

36 <sup>17</sup> Department of Intensive Care and Poison Control, Ha Dong General Hospital, Hanoi,  
37 Vietnam

38 <sup>18</sup> Stroke Center, Bach Mai Hospital, Hanoi, Vietnam

39 <sup>19</sup> Poison Control Center, Bach Mai Hospital, Hanoi, Vietnam

40 <sup>20</sup> Department of Internal Medicine, Faculty of Medicine, University of Medicine and  
41 Pharmacy, Vietnam National University, Hanoi, Vietnam

42 <sup>21</sup> Department of Emergency and Critical Care Medicine, Thai Binh University of Medicine  
43 and Pharmacy, Thai Binh, Vietnam

44 <sup>22</sup> Department of Basic Medical Sciences, University of Medicine and Pharmacy, Vietnam  
45 National University, Hanoi, Vietnam

46 <sup>23</sup> Department of Infectious Diseases, Faculty of Medicine, University of Medicine and  
47 Pharmacy, Vietnam National University, Hanoi, Vietnam

48 <sup>24</sup> Respiratory Center, Bach Mai Hospital, Hanoi, Vietnam

49 <sup>25</sup> Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam

50 **\*Corresponding author:**

51 Co Xuan Dao, MD, PhD

52 Center for Critical Care Medicine, Bach Mai Hospital, No. 78, Giai Phong Road, Dong Da

53 District, Hanoi 100000, Vietnam

54 Email: [daoxuanco@gmail.com](mailto:daoxuanco@gmail.com)

55 Phone number: +84.93.713.8868

56 ORCID: <https://orcid.org/0000-0002-3182-2993>

57

58 **Running Head:** Simplified Radiographic Assessment of Lung Edema score for predicting  
59 mortality in critically ill COVID-19 patients in Vietnam

60 **Article Type:** Research / Original Paper

61 **Word Count:**

62 - Abstract: 360 words

63 - Formal scientific presentations: 5487 words and 60 references, plus a structured abstract

64 **Figure/Table:** 5

65

66

67

68

69

70

## 71 **ABSTRACT**

### 72 **Background**

73 Evaluating the prognosis of COVID-19 patients who may be at risk of mortality using the  
74 simple chest X-ray (CXR) severity scoring systems provides valuable insights for treatment  
75 decisions. This study aimed to assess how well the simplified Radiographic Assessment of  
76 Lung Edema (RALE) score could predict the death of critically ill COVID-19 patients in  
77 Vietnam.

### 78 **Methods**

79 From July 30 to October 15, 2021, we conducted a cross-sectional study on critically ill  
80 COVID-19 adult patients at an intensive care centre in Vietnam. We calculated the areas  
81 under the receiver operator characteristic (ROC) curve (AUROC) to determine how well the  
82 simplified RALE score could predict hospital mortality. In a frontal CXR, the simplified  
83 RALE score assigns a score to each lung, ranging from 0 to 4. The overall severity score is  
84 the sum of points from both lungs, with a maximum possible score of 8. We also utilized  
85 ROC curve analysis to find the best cut-off value for this score. Finally, we utilized logistic  
86 regression to identify the association of simplified RALE score with hospital mortality.

### 87 **Results**

88 Of 105 patients, 40.0% were men, the median age was 61.0 years (Q1-Q3: 52.0-71.0), and  
89 79.0% of patients died in the hospital. Most patients exhibited bilateral lung opacities on their  
90 admission CXRs (99.0%; 100/102), with the highest occurrence of opacity distribution  
91 spanning three (18.3%; 19/104) to four quadrants of the lungs (74.0%; 77/104) and a high  
92 median simplified RALE score of 8.0 (Q1-Q3: 6.0-8.0). The simplified RALE score  
93 (AUROC: 0.747 [95% CI: 0.617-0.877]; cut-off value  $\geq 5.5$ ; sensitivity: 93.9%; specificity:

94 45.5%;  $P_{\text{AUROC}} < 0.001$ ) demonstrated a good discriminatory ability in predicting hospital  
95 mortality. After adjusting for confounding factors such as age, gender, Charlson Comorbidity  
96 Index, serum interleukin-6 level upon admission, and admission severity scoring systems, the  
97 simplified RALE score of  $\geq 5.5$  (adjusted OR: 18.437; 95% CI: 3.215-105.741;  $p = 0.001$ ) was  
98 independently associated with an increased risk of hospital mortality.

## 99 **Conclusions**

100 This study focused on a highly selected cohort of critically ill COVID-19 patients with a high  
101 simplified RALE score and a high mortality rate. Beyond its good discriminatory ability in  
102 predicting hospital mortality, the simplified RALE score also emerged as an independent  
103 predictor of hospital mortality.

104 **Keywords:** Acute Respiratory Distress Syndrome, Brixia scoring system, Chest X-ray,  
105 Consolidation, COVID-19, COVID-19 pandemic, CXR severity score, Ground-glass  
106 opacities, Intensive care unit, Reticular interstitial thickening, Lung involvement, Mortality,  
107 Pulmonary infection, RALE scoring system, SARS-CoV-2, Total severity score.

108

109

110

111

112

113

114

## 115 INTRODUCTION

116 Since the first reports of coronavirus disease 2019 (COVID-19) cases from Wuhan, a city in  
117 the Hubei Province of China, at the end of 2019, cases have emerged across all continents.(1-  
118 3) As of February 4, 2024, there have been more than 770 million confirmed cases of  
119 COVID-19 worldwide.(4) However, the reported case counts underestimate the overall  
120 burden of COVID-19, as only a fraction of acute infections are diagnosed and reported.  
121 During the COVID-19 pandemic, most countries lack sufficient diagnostic tools due to the  
122 rising daily number of reported cases. Therefore, it becomes crucial to correctly categorize  
123 COVID-19 patients based on the severity of their symptoms for efficient resource  
124 distribution.(5) Specifically, the value of oxygen saturation in the peripheral blood ( $SpO_2$ ) is  
125 one of the first measures checked for each patient on admission; it often reflects the degree of  
126 lung function impairment. The requirement to transfer patients with COVID-19 to an  
127 intensive care unit (ICU) depends mainly on their  $SpO_2$  and concurrent comorbidities.(6)  
128 Some experts have suggested that imaging can help determine this need.

129 A chest X-ray (CXR) has been suggested as a tool to predict the severity of COVID-19 by  
130 assessing lung involvement and offering insights into the prognosis of the COVID-19  
131 infection. A previous study introduced the CXR scoring system for quantifying the severity  
132 and progression of lung abnormalities in COVID-19 pneumonia.(7) This system evaluated  
133 the extent of COVID-19 pulmonary abnormalities on CXR using a semiquantitative severity  
134 score ranging from 0 to 3, with 1-point increments, across six lung zones (total range 0–18),  
135 correlated these findings with clinical data, and assessed interobserver agreement.  
136 Interestingly, the study revealed a moderate to almost perfect interobserver agreement and  
137 identified significant but weak correlations with clinical parameters.(7) As a result,  
138 integration of CXR into the classification of COVID-19 patients is a potential avenue for

139 further exploration. Another previous study introduced a CXR scoring system called the  
140 Brixia score.(8) This score is a valuable tool for assessing the severity of COVID-19  
141 infection. By evaluating the extent and characteristics of lung abnormalities, the Brixia score  
142 offers insights into pulmonary involvement using an 18-point severity scale.(8) While CXR is  
143 considered not sensitive in detecting early-stage pulmonary involvement, the Brixia score  
144 remains a useful diagnostic tool for identifying the rapid progression of lung abnormalities in  
145 COVID-19 patients, particularly in ICUs.(8)

146 To further understand the radiographic features of COVID-19, a retrospective study examines  
147 the progression and severity of CXR findings associated with the disease.(9) Additionally,  
148 this study adapts and simplifies the original Radiographic Assessment of Lung Edema  
149 (original RALE)(10) score to quantify the extent of infection and calculate a severity score  
150 for COVID-19. While 20% of patients did not exhibit any abnormalities on their CXR  
151 throughout the illness, this study reveals that common abnormal CXR findings included  
152 consolidation and ground-glass opacities.(9) These abnormalities were distributed bilaterally,  
153 peripherally, and in the lower lung zones. The CXR severity score progressively intensified  
154 during the illness, reaching its peak severity between 10 to 12 days after the onset of  
155 symptoms.(9) Although this study reveals that baseline CXR sensitivity is lower than those of  
156 real-time reverse transcription-polymerase chain reaction (RT-PCR) tests and computed  
157 tomography (CT) scans, it still suggests that CXR have a role in the initial screening for  
158 COVID-19 and identifying the rapid progression of lung abnormalities in COVID-19  
159 patients.(9)

160 Two recent published studies also show that the adaptation and simplification of the original  
161 RALE score proved valuable in predicting the mortality of critically ill patients with COVID-  
162 19.(11, 12) However, limited data on this simplified score's external validity are available.

163 Therefore, the present study aimed to assess how well the simplified RALE score could  
164 predict the death of critically ill patients with COVID-19 in Vietnam.

165

## 166 **METHODS**

### 167 **Study design and setting**

168 From July 30 to October 15, 2021, we conducted a cross-sectional study on critically ill  
169 COVID-19 patients with the Delta variant at the Intensive Care Centre for the Treatment of  
170 Critically Ill Patients with COVID-19 (study centre) in Ho Chi Minh City (HCMC), Vietnam.  
171 This centre was a field hospital with 360 beds and was affiliated with the Bach Mai Hospital  
172 (BMH) in Hanoi, Vietnam. BMH is designated as the central hospital in northern Vietnam by  
173 the Ministry of Health (MOH) of Vietnam.(13) It is a large general hospital with 3,200 beds.

174 In July 2021, HCMC faced a severe Delta variant COVID-19 outbreak, which led to a high  
175 demand for ICUs for critically ill patients.(14, 15) In response, the MOH established four  
176 specialized Intensive Care Centres for the Treatment of Critically Ill Patients with COVID-19  
177 on July 30, 2021, which could only receive patients transferred from lower-level hospitals in  
178 HCMC. The study centre was under the management of BMH and was called Field Hospital  
179 Number 16. The study centre had a capacity of 500 beds at its peak and later reduced it to  
180 360. The study centre stopped operating on April 30, 2022, after the COVID-19 cases  
181 declined. The Director of BMH also served as the Director of the study centre. Likewise, two  
182 Deputy Directors of the study centre were from the Centre for Emergency Medicine of BMH  
183 in Hanoi and the Director Board of Hung Vuong Hospital in HCMC. The study centre had  
184 968 medical staff and volunteers in total, and more than half of them (542 medical staff) were  
185 from BMH. They came from different departments and centres of BMH, such as Emergency,



186 Intensive Care, Tropical Diseases, Respiratory, Clinical Nutrition, Nephro-Urology and  
187 Dialysis, Neurology, Cardiovascular, Infection Control, Haematology and Blood Transfusion,  
188 Radiology, Biochemistry, and Microbiology.

### 189 **Participants**

190 This study included patients aged 18 years or older who were critically ill with COVID-19  
191 and presented to the study centre. We defined a case of COVID-19 as a person with  
192 laboratory confirmation of COVID-19 infection, regardless of clinical or epidemiological  
193 criteria.(16, 17) Laboratory confirmation of COVID-19 infection was based on a positive RT-  
194 PCR test using samples obtained from the respiratory tract by nasopharyngeal swab, throat or  
195 mouth swab, or tracheal lavage fluid.(18) We excluded patients who did not have CXRs  
196 between hospital admission and the end of the first day.

### 197 **Data collection**

198 The data for each study patient were recorded from the same unified case record forms  
199 (CRFs). Data was entered into the study database by the online password-protected CRF.  
200 Patient identifiers were not entered in the database to protect patients' confidentiality.

### 201 **Variables**

202 The CRF contained four sections, which included variables mainly based on the COVID-19  
203 Treatment Guidelines of the National Institutes of Health(19) and collected by fully trained  
204 clinicians, such as information on:

205 (i) The first section focused on baseline characteristics, such as: prehospital care (e.g., prior  
206 hospitalization, prehospital airway, prehospital oxygen), demographics (i.e., age and gender),  
207 documented comorbidities (e.g., cerebrovascular disease, chronic cardiac failure, coronary

208 artery disease/myocardial infarction, hypertension, chronic obstructive pulmonary  
209 disease/asthma, other chronic pulmonary disease, tuberculosis, chronic renal failure, and  
210 diabetes mellitus), and details of admission. We also used the 19 comorbidity categories to  
211 compute the Charlson Comorbidity Index (CCI) Score, which measures the predicted  
212 mortality rate based on the presence of comorbidities.(20) A score of zero indicates that no  
213 comorbidities were detected; the higher the score, the higher the expected mortality rate  
214 is.(20-22)

215 (ii) The second section comprised characteristics upon admission, such as vital signs (e.g.,  
216 heart rate, respiration rate, arterial blood pressure, and body temperature), laboratory  
217 parameters (e.g., interleukin-6 (IL-6)), chest X-ray (CXR) findings (e.g., bilateral opacities,  
218 number of involved quadrants, and severity of COVID-19 based on lung involvement), gas  
219 exchange (e.g., the partial pressure of oxygen ( $\text{PaO}_2$ ) and carbon dioxide ( $\text{PaCO}_2$ ) in the  
220 arterial blood, the acidity of the blood (pH), and the ratio of partial pressure of oxygen in  
221 arterial blood to the fraction of inspiratory oxygen concentration ( $\text{PaO}_2/\text{FiO}_2$ )), and severity  
222 scoring systems (e.g., Sequential Organ Failure Assessment (SOFA) score(23), Acute  
223 Physiology and Chronic Health Evaluation II (APACHE II) score(24), and Confusion, Urea  
224  $>7$  mmol/L, Respiratory Rate  $\geq 30$  breaths/min, Blood Pressure  $<90$  mm Hg (Systolic) or  $<60$   
225 mm Hg (Diastolic), Age  $\geq 65$  Years (CURB-65) score(25)). Serum IL-6 was measured using  
226 the Elecsys IL-6 immunoassay (Roche® Cobas E411 analyser), an in vitro diagnostic test for  
227 quantitatively determining IL-6 in human serum and plasma. The measuring range is from  
228 1.5 – 5000pg/mL. Data on the IL-6 levels were collected prospectively on a CRF from  
229 hospital admission until the end of the first day. In the present study, we defined the IL-6  
230 level as 5000pg/mL when values were above the measuring range ( $>5000$ pg/mL).  
231 Prospectively, we collected all necessary data elements for calculating the SOFA score,  
232 APACHE II score, and CURB-65 score within the time window from admission until 24

233 hours later, entered these data into an online CRF, and stored them in a database for the  
234 subsequent analysis. The CXRs were performed for severely and critically ill patients with  
235 COVID-19 in a single frontal projection with an anteroposterior view by using a compact and  
236 portable X-ray device (FDR nano, Model/Serial: DR-XD 1000, Fujifilm Techno Products  
237 Co., Ltd) conveniently brought to the patient's bedside in the hospital or emergency room.  
238 The X-ray tube was connected to a flexible arm, allowing the technician to position it over  
239 the patient and place an X-ray film holder or image recording plate underneath. In  
240 hospitalized patients with COVID-19, we performed a portable CRX as the initial evaluation  
241 for pulmonary complications and lung involvement. Chest computed tomography (CT) scans  
242 were reserved for specific situations that might change clinical management, partly to  
243 minimize infection control issues related to transport. These practices align with the  
244 recommendations from the American College of Radiology(26). The evaluation of CXR  
245 findings, which were taken from hospital admission until the end of the first day and included  
246 bilateral opacities, the extent of lung involvement across quadrants, and the severity of  
247 COVID-19 based on lung assessments, was a two-step process. Initially, a radiology resident  
248 in their third year reviewed the CXRs. Following this, a thoracic radiologist with ten years of  
249 experience independently validated the findings. Both professionals were unaware of other  
250 clinical variables and outcomes. In case of any discrepancies identified in the images, they  
251 collaborated to reach a consensus. We adapted and simplified the original RALE score(10) to  
252 create a simplified RALE score for assessing the severity of COVID-19 based on lung  
253 involvement. This approach has also been used in prior published studies to quantify the  
254 extent of pulmonary infection in COVID-19 cases.(9, 11, 12, 17) In a frontal CXR, the  
255 simplified RALE scoring system assigns a score to each lung, ranging from 0 to 4. This score  
256 reflects the attendance of specific abnormalities. The system divides each lung into four  
257 zones, and abnormalities such as consolidation, ground-glass opacification, and reticular

258 interstitial thickening are assigned a score of 1 in each zone (S1 Fig in S1 File). A score of 0  
259 indicates no involvement, while a score of 1 corresponds to less than 25% involvement, a  
260 score of 2 represents 25% to less than 50% involvement, a score of 3 signifies 50% to less  
261 than 75% involvement, and a score of 4 indicates 75% or greater involvement. The overall  
262 severity score is the sum of points from both lungs, with a maximum possible score of 8.  
263 Based on the simplified RALE score upon admission, the patients were classified into three  
264 severity groups as follows: mild (a score of 1 to 2), moderate (a score of 3 to 6), and severe (a  
265 score of 7 to 8).

266 (iii) The third section captured life-sustaining treatments provided during the ICU stay, such  
267 as respiratory support on the first day of admission (e.g., oxygen supplements and mechanical  
268 ventilation) and adjunctive therapies (e.g., prone positioning, recruitment maneuvers,  
269 extracorporeal membrane oxygenation, antiviral drugs, antibiotics, corticosteroids, heparin,  
270 antiplatelet drugs, novel oral anticoagulants, recombinant humanized anti-IL-6 receptor  
271 monoclonal antibody, continuous sedation, continuous neuromuscular blocking agents, renal  
272 replacement therapy, cytokine adsorption therapy, tracheostomy, and inhaled vasodilators).

273 (iv) The fourth section is concerned with complications (e.g., hospital-acquired pneumonia  
274 (HAP), hypoxemic respiratory failure/ARDS, diffuse alveolar damage, secondary bacterial  
275 infections, sepsis and septic shock, cardiac injury, arrhythmia, acute kidney injury, liver  
276 dysfunction, multi-organ failure, thromboembolism, gastrointestinal bleeding, and  
277 pneumothorax/pneumomediastinum) and clinical outcomes (e.g., hospital mortality). HAP is  
278 defined as pneumonia that occurs 48 hours or more after admission and does not appear to be  
279 incubating at the time of admission.(27) To diagnose and classify ARDS, we applied the  
280 Berlin criteria, which categorize ARDS severity based on the  $\text{PaO}_2/\text{FiO}_2$  ratio as follows:  
281 mild ( $200 < \text{PaO}_2/\text{FiO}_2 \leq 300$  mmHg), moderate ( $100 < \text{PaO}_2/\text{FiO}_2 \leq 200$  mmHg), and severe

282 (PaO<sub>2</sub>/FiO<sub>2</sub> ≤ 100 mmHg), with a minimum positive end-expiratory pressure (PEEP) of 5  
 283 cmH<sub>2</sub>O applied to the lungs at the end of each breath.(28, 29). Additionally, septic shock is  
 284 identified as a clinical construct of sepsis characterized by persisting hypotension requiring  
 285 vasopressors to maintain a mean arterial pressure ≥ 65 mmHg, along with a serum lactate  
 286 level > 2 mmol/L (18 mg/dL) despite adequate volume resuscitation.(30) Lastly,  
 287 thromboembolism encompasses venous thromboembolism (i.e., deep vein thrombosis and  
 288 pulmonary embolism), arterial events (i.e., stroke, limb ischemia, and myocardial infarction),  
 289 and microvascular thrombosis (e.g., microvascular thrombosis in the lungs).(19)

290 We followed all patients till hospital discharge or death in the ICU/hospital, whichever was  
 291 earliest.

## 292 **Outcome measures**

293 The primary outcome was hospital mortality, which we defined as death from any cause  
 294 during the hospitalization. We also examined the secondary outcomes, such as complications  
 295 (e.g., ARDS) and hospital lengths of stay.

## 296 **Sample size**

297 In this cross-sectional study, the primary outcome was hospital mortality. Therefore, we used  
 298 the formula to find the minimum sample size for estimating a population proportion with a  
 299 confidence level of 90%, a confidence interval (margin of error) of ±8.02%, and an assumed  
 300 population proportion of 54.64%, based on the hospital mortality (54.64%) reported in a  
 301 previously published study(31). As a result, our sample size should be at least 105 patients,  
 302 which might be large enough to reflect a normal distribution.

$$303 \quad n = \frac{z^2 x \hat{p}(1 - \hat{p})}{\varepsilon^2}$$

304 where:

305 *z* is the *z* score (*z* score for a 90% confidence level is 1.65)

306  $\varepsilon$  is the margin of error ( $\varepsilon$  for a confidence interval of  $\pm 8.02\%$  is 0.0802)

307  $\hat{p}$  is the population proportion ( $\hat{p}$  for a population proportion of 54.64% is 0.5464)

308 *n* is the sample size

### 309 **Statistical analyses**

310 We used IBM® SPSS® Statistics 22.0 (IBM Corp., Armonk, United States of America) and  
311 Analyse-it statistical software (Analyse-it Software, Ltd., Leeds, United Kingdom) for data  
312 analysis. We report the data as numbers (no.) and percentages (%) for categorical variables  
313 and medians and interquartile ranges (Q1-Q3) or means and standard deviations (SDs) for  
314 continuous variables. Furthermore, comparisons were made between survival and death in the  
315 hospital for each variable using the Chi-squared or Fisher's exact test for categorical  
316 variables and the Mann-Whitney U test, Kruskal-Wallis test, or one-way analysis of variance  
317 for continuous variables.

318 To evaluate how well the simplified RALE score, CCI score, admission serum IL-6 level,  
319 SOFA score, APACHE II score, and CURB-65 score could differentiate between patients  
320 who survived and those who died in the hospital, we plotted receiver operator characteristic  
321 (ROC) curves and calculated areas under the ROC curve (AUROCs) for each score or level.  
322 We also used the ROC curve analysis to determine the best cut-off value for each score or  
323 level, which was the point that gave the highest Youden's index (i.e., sensitivity + specificity  
324 - 1). Then, we divided the patients into two groups based on their score or level: one that was  
325 less than the cut-off or another greater than or equal to the cut-off value. Additionally, we  
326 compared the AUROCs of simplified RALE score with those of the serum IL-6 level, CCI  
327 score, SOFA score, APACHE II score, and CURB-65 score to see which one was better at

328 predicting deaths in the hospital using the Z-statistics. Finally, we calculated correlation  
329 coefficients (Rs) using Spearman's rho to explore the relationship between simplified RALE  
330 score and each score or level.

331 We assessed the association of simplified RALE Score with hospital mortality using logistic  
332 regression analysis. To reduce the number of predictors and the multicollinearity issue and  
333 resolve the overfitting, we used different methods to select variables as follows: (a) we put all  
334 variables of demographics, documented comorbidities, clinical characteristics, CXR findings,  
335 laboratory investigations, gas exchange, severity scoring systems, first-day respiratory  
336 support, adjunctive therapies, complications into the univariable logistic regression model;  
337 (b) we selected variables if the P-value was  $<0.05$  in the univariable analysis between death  
338 and survival in the hospital, as well as those that are clinically crucial, to put in the  
339 multivariable logistic regression model. These variables included demographics (i.e., age  $\geq$   
340 60 years, gender (male)), documented comorbidities (i.e., CCI score  $\geq$ cut-off value), CXR  
341 findings (i.e., simplified RALE Score  $\geq$ cut-off value), laboratory investigations (i.e.,  
342 admission serum IL-6 level  $\geq$ cut-off value), severity scoring systems (i.e., SOFA score  $\geq$  cut-  
343 off value, CURB-65 score  $\geq$ cut-off value). Using a stepwise backward elimination method,  
344 we started with the full multivariable logistic regression model that included the selected  
345 variables. This method then deleted the least statistically significant variables stepwise from  
346 the full model until all remaining variables were independently associated with hospital  
347 mortality in the final model. We presented the odds ratios (ORs) and 95% confidence  
348 intervals (CIs) in the univariable logistic regression model and the adjusted ORs (AORs) and  
349 95% CIs in the multivariable logistic regression model.

350 The significance levels were two-tailed for all analyses, and we considered the  $P < 0.05$  as a  
351 statistically significant value.

**352 Ethical issues**

353 This study was approved by the Scientific and Ethics Committees of Bach Mai Hospital  
354 (Approval number: 3412/QĐ-BM) and conducted according to the principles of the  
355 Declaration of Helsinki. The Bach Mai Hospital Scientific and Ethics Committees waived the  
356 written informed consent for this non-interventional study. Verbal informed consents were  
357 directly obtained from patients or, when unavailable, from family members over the phone or  
358 at the Intensive Care Centre for the Treatment of Critically Ill Patients with COVID-19 and  
359 witnessed by the on-duty medical staff. Public notification of this study was made by  
360 published posting, according to the Strengthening the Reporting of Observational Studies in  
361 Epidemiology (STROBE): Explanation and Elaboration - the STROBE Statement - Checklist  
362 of items that should be included in reports of cross-sectional studies. The authors who  
363 performed the data analysis kept the data set in password-protected systems and only  
364 presented anonymized data.

365

**366 RESULTS****367 Baseline characteristics and clinical outcomes**

368 Of 105 patients, 40.0% were men, and the median age was 61.0 years (Q1-Q3: 52.0-71.0)  
369 (Table 1). Upon admission, nearly all patients (99.0%; 100/102) exhibited bilateral lung  
370 opacities on their CXR (Table 2). These opacities were most frequently distributed across  
371 three (18.3%; 19/104) and four quadrants of lungs (74.0%; 77/104). Additionally, the patients  
372 had a high median simplified RALE score of 8.0 (Q1-Q3: 6.0-8.0) (Table 2) and a low mean  
373 PaO<sub>2</sub>/FiO<sub>2</sub> ratio of 101.66 (SD: 58.20) (Table 2). Elevated mean serum IL-6 level was  
374 observed upon admission (99.76pg/mL; SD: 174.33) (Table 2). The median SOFA score was



375 4.0 (Q1-Q3: 2.0-5.0), median APACHE II score was 8.0 (Q1-Q3: 3.0-12.0), and median  
376 CURB-65 score was 1.0 (Q1-Q3: 1.0-2.0) within the time window from admission until 24  
377 hours later (Table 2). In general, 79.0% (83/105) of the patients died in the hospital (Tables 1  
378 and 2). As shown in Tables 1 and 2 and S1 to S5 Tables (S1 File), we also compared the  
379 factors between survivors and non-survivors in the hospital, such as prehospital care,  
380 demographics, comorbidities, vital signs, laboratory investigations, CXR findings, severity  
381 scoring systems, treatments, and complications.

382

383

384

385

386

387

388

389

390

391

392

393

394

395 **Table 1.** Baseline characteristics of critically ill COVID-19 patients with the Delta variant, according to hospital survivability

Variables	All cases n=105	Survived n=22	Died n=83	P value <sup>a</sup>
<b>Demographics</b>				
Age (year), median (Q1-Q3)	61.0 (52.0-71.0)	53.5 (48.5-62.0)	62.0 (54.0-73.0)	0.009
Gender (male), no. (%)	42 (40.0)	6 (27.3)	36 (43.4)	0.171
<b>Comorbidities</b>				
Cerebrovascular disease, no. (%), n=78	5 (6.4)	0 (0.0)	5 (7.7)	0.583
Chronic cardiac failure, no. (%), n=78	4 (5.1)	2 (15.4)	2 (3.1)	0.127
Coronary artery disease/MI, no. (%), n=78	4 (5.1)	1 (7.7)	3 (4.6)	0.525
Hypertension, no. (%), n=78	50 (64.1)	7 (53.8)	43 (66.2)	0.528
COPD/asthma, no. (%), n=78	1 (1.3)	0 (0.0)	1 (1.5)	>0.999
Other chronic pulmonary disease, no. (%), n=78	1 (1.3)	0 (0.0)	1 (1.5)	>0.999
Tuberculosis, no. (%), n=78	1 (1.3)	0 (0.0)	1 (1.5)	>0.999
Chronic renal failure, no. (%), n=78	1 (1.3)	0 (0.0)	1 (1.5)	>0.999
Diabetes mellitus, no. (%), n=78	40 (51.3)	5 (38.5)	35 (53.8)	0.311
CCI score, median (Q1-Q3), n=102	2.0 (1.0-4.0)	1.0 (0.0-2.5)	2.0 (1.0-4.0)	0.023
<b>Vital signs upon admission</b>				
HR (beats/min), median (Q1-Q3), n=99	92.0 (80.0-100.0)	90.0 (84.75-100.75)	95.0 (80.0-100.0)	0.871
RR (breaths/min), median (Q1-Q3), n=97	26.0 (25.0-30.0)	25.0 (22.0-27.0)	28.0 (25.0-31.5)	0.006

Systolic BP (mmHg), mean (SD), n=99	124.97 (17.58)	127.59 (15.03)	124.22 (18.27)	0.573
Diastolic BP (mmHg), mean (SD), n=98	75.91 (11.51)	79.0 (8.40)	75.06 (12.13)	0.195
Body temperature (°C), mean (SD), n=95	36.95 (0.37)	36.94 (0.15)	36.95 (0.41)	0.390

<sup>a</sup> The comparison between patients who survived and those who died in the hospital.

**Abbreviations:** **BP**, blood pressure; **CCI**, Charlson Comorbidity Index; **COPD**, chronic obstructive pulmonary disease; **HR**, heart rate; **MI**, myocardial infarction; **no.**, number of patients; **Q**, quartile; **RR**, respiration rate; **SD**, standard deviation.

396

397 **Table 2.** Laboratory investigations, gas exchange, chest X-ray findings, and severity scoring systems of critically ill COVID-19 patients with the

398 Delta variant upon admission, according to hospital survivability

Variables	All cases n=105	Survived n=22	Died n=83	P value <sup>a</sup>
<b>Laboratory investigations</b>				
WBC (G/L), mean (SD)	12.94 (5.73)	11.94 (4.78)	13.21 (5.95)	0.587
Hemoglobin (g/dL), mean (SD)	123.79 (25.81)	118.97 (29.59)	125.06 (24.75)	0.317
Platelet count (G/L), mean (SD)	270.15 (187.08)	310.5 (330.35)	259.46 (126.04)	0.937
CRP (mg/L), mean (SD), n=90	10.85 (10.85)	13.96 (26.87)	9.96 (4.99)	0.295
Glucose (mmol/L), mean (SD), n=101	11.60 (6.30)	11.98 (9.46)	11.52 (5.39)	0.473
Ure (mmol/L), mean (SD), n=104	8.56 (6.92)	6.9 (6.81)	9.01 (6.92)	0.005
Creatinine (μmol/L), mean (SD), n=104	89.79 (47.51)	79.59 (38.51)	92.52 (49.49)	0.040
INR, mean (SD)	3.52 (16.65)	5.76 (20.83)	2.92 (15.46)	0.576
Interleukin 6 (pg/mL), mean (SD), n=90	99.76 (174.33)	66.68 (85.36)	109.83 (192.86)	0.128

<b>Gas exchange</b>				
pH, mean (SD), n=63	7.41 (0.11)	7.48 (0.05)	7.39 (0.11)	0.006
PaO <sub>2</sub> (mmHg), mean (SD), n=63	80.98 (48.85)	84.18 (27.03)	80.31 (52.49)	0.135
PaO <sub>2</sub> /FiO <sub>2</sub> ratio, mean (SD), n=62	101.66 (58.20)	126.74 (57.98)	96.26 (57.38)	0.045
SpO <sub>2</sub> (%), mean (SD), n=87	92.54 (5.29)	94.38 (4.26)	92.13 (5.44)	0.042
<b>Chest X-ray findings</b>				
Bilateral opacities, no. (%), n=102	100 (99.0)	19 (95.0)	82 (100.0)	0.196
Number of involved quadrants, n=104				<0.001
1 quadrant, no. (%)	1 (1.0)	1 (4.8)	0 (0.0)	
2 quadrants, no. (%)	7 (6.7)	6 (28.6)	1 (1.2)	
3 quadrants, no. (%)	19 (18.3)	6 (28.6)	13 (15.7)	
4 quadrants, no. (%)	77 (74.0)	8 (38.1)	69 (83.1)	
Simplified RALE score, median (Q1-Q3), n=105	8.0 (6.0-8.0)	6.0 (4.0-8.0)	8.0 (7.0-8.0)	<0.001
<b>Severity scoring system</b>				
SOFA score, median (Q1-Q3), n=79	4.0 (2.0-5.0)	2.0 (0.0-3.0)	4.0 (2.25-5.0)	0.002
APACHE II score, median (Q1-Q3), n=75	8.0 (3.0-12.0)	7.0 (2.0-8.75)	9.0 (4.0-13.0)	0.077
CURB-65 score, median (Q1-Q3), n=99	1.0 (1.0-2.0)	0.5 (0.0-1.0)	1.0 (1.0-2.0)	<0.001

<sup>a</sup> The comparison between patients who survived and those who died in the hospital.

**Abbreviations:** **APACHE II**, Acute Physiology and Chronic Health Evaluation II; **CRP**, C-reactive protein; **CURB-65**, Confusion, Urea >7 mmol/L, Respiratory Rate ≥30 breaths/min, Blood Pressure <90 mm Hg (Systolic) or <60 mm Hg (Diastolic), and Age ≥65 Years Criteria; **IL-6**, Interleukin 6; **INR**, international normalized ratio; **no.**, number of patients; **PaO<sub>2</sub>**, partial pressure of oxygen in arterial blood; **PaO<sub>2</sub>/FiO<sub>2</sub>**, the ratio of partial pressure of oxygen in arterial blood to the fraction of inspiratory oxygen concentration; **pH**, the acidity of the blood; **Q**, quartile; **SD**, standard deviation; **SOFA**, Sequential Organ Failure Assessment; **SpO<sub>2</sub>**, peripheral capillary oxygen saturation; **RALE**, Radiographic Assessment of Lung Edema; **WBC**, white blood cell.

400 **Overall predictive performance of simplified RALE score and other severity scoring**  
401 **systems**

402 Unlike the PaO<sub>2</sub>/FiO<sub>2</sub> ratio (AUROC: 0.306 [95% CI: 0.124-0.487]; cut-off value  $\geq$ 46.5%;  
403 sensitivity: 98.0%; specificity: 9.1%; P<sub>AUROC</sub> =0.045), serum IL-6 level (AUROC: 0.610  
404 [95% CI: 0.459-0.761]; cut-off value  $\geq$ 15.8pg/mL; sensitivity: 84.1%; specificity: 42.9%;  
405 P<sub>AUROC</sub> =0.128), and APACHE II score (AUROC: 0.645 [95% CI: 0.504-0.785]; cut-off  
406 value  $\geq$ 11.5; sensitivity: 33.9%; specificity: 93.8; P<sub>AUROC</sub> =0.078) (S6 Table in S1 File), the  
407 simplified RALE score (AUROC: 0.747 [95% CI: 0.617-0.877]; cut-off value  $\geq$ 5.5;  
408 sensitivity: 93.9%; specificity: 45.5%; P<sub>AUROC</sub> <0.001) demonstrated the good discriminatory  
409 ability in predicting hospital mortality (Fig 1, S6 Table in S1 File). Additionally, both the  
410 SOFA score (AUROC: 0.747 [95% CI: 0.604-0.890]; cut-off value  $\geq$ 3.5; sensitivity: 62.5%;  
411 specificity: 80.0%; P<sub>AUROC</sub> = 0.003) and the CURB-65 score (AUROC: 0.776 [95% CI:  
412 0.665-0.887]; cut-off value  $\geq$ 0.5; sensitivity: 89.9%; specificity: 50.0%; P<sub>AUROC</sub> = 0.001) also  
413 exhibited the good discrimination in predicting hospital mortality (Fig 1, S6 Table in S1 File).  
414 S6 Table (S1 File) summarizes the overall predictive performance of other risk factors for  
415 hospital mortality in critically ill COVID-19 patients with the Delta variant.

416 **Figure 1.** Overall predictive performance of simplified RALE, SOFA, CURB-65, and  
417 APACHE II scores for hospital mortality in critically ill COVID-19 patients with the Delta  
418 variant: The area under the ROC curves of the simplified RALE (AUROC: 0.747 [95% CI:  
419 0.617-0.877]; cut-off value  $\geq$ 5.5; sensitivity: 93.9%; specificity: 45.5%; P<sub>AUROC</sub> <0.001), the  
420 SOFA score (AUROC: 0.747 [95% CI: 0.604-0.890]; cut-off value  $\geq$ 3.5; sensitivity: 62.5%;  
421 specificity: 80.0%; P<sub>AUROC</sub> = 0.003), CURB-65 scores (AUROC: 0.776 [95% CI: 0.665-  
422 0.887]; cut-off value  $\geq$ 0.5; sensitivity: 89.9%; specificity: 50.0%; P<sub>AUROC</sub> = 0.001), and  
423 APACHE II score (AUROC: 0.645 [95% CI: 0.504-0.785]; cut-off value  $\geq$ 11.5; sensitivity:

424 33.9%; specificity: 93.8;  $P_{\text{AUROC}} = 0.078$ ) for predicting hospital mortality in critically ill  
425 COVID-19 patients with the Delta variant. (Abbreviations: **APACHE II**, Acute Physiology  
426 and Chronic Health Evaluation II; **AUROC**, areas under the receiver operating characteristic  
427 curve; **CI**, confidence interval; **CURB-65**, Confusion, Urea  $>7$  mmol/L, Respiratory Rate  
428  $\geq 30$  breaths/min, Blood Pressure  $<90$  mm Hg (Systolic) or  $<60$  mm Hg (Diastolic), Age  $\geq 65$   
429 Years; **RALE**, Radiographic Assessment of Lung Edema; **SOFA**, Sequential Organ Failure  
430 Assessment).

431 S7 Table (S1 File) shows the differences between the AUROC curves among different test-  
432 pairwise, of which the AUROCs for predicting hospital mortality did not differ significantly  
433 between the simplified RALE score and SOFA score (AUROC difference: 0.015; 95% CI: -  
434 0.117 to 0.148; Z-statistic: 0.23;  $p = 0.819$ ) and the simplified RALE score and CURB-65  
435 score (AUROC difference: 0.046; 95% CI: -0.110 to 0.203; Z-statistic: 0.58;  $p = 0.562$ ). S6  
436 Table (S1 File) also present the AUROC differences between other risk factors for hospital  
437 mortality in critically ill COVID-19 patients with the Delta variant.

#### 438 **Spearman's correlation between simplified RALE score and severity of illness**

439 We used the Spearman's rank correlation coefficient to examine the associations between  
440 simplified RALE score and various severity scoring systems upon admission (Table 3, S8  
441 Table in S1 File). We observed a modest correlation between the simplified RALE score and  
442 the serum IL-6 level ( $R_s = 0.226$ ;  $p = 0.032$ ), SOFA score ( $R_s = 0.344$ ;  $p = 0.002$ ), APACHE II  
443 score ( $R_s = 0.231$ ;  $p = 0.046$ ), and CURB-65 score ( $R_s = 0.235$ ;  $p = 0.019$ ). Spearman's  
444 correlation between other severity scoring systems upon admission is present in S8 Table (S1  
445 File).

#### 446 **Association of simplified RALE score with hospital mortality**

447 In the univariable logistic regression analysis, the simplified RALE score  $\geq 5.5$  (OR: 13.000;  
448 95% CI: 3.786-44.637;  $p < 0.001$ ) was significantly associated with an increased risk of  
449 hospital mortality (Table 4). In the multivariable logistic regression analysis, after accounting  
450 for confounding variables such as age ( $\geq 60$  years), male gender, CCI score ( $\geq 1.5$ ), serum IL-6  
451 levels upon admission ( $\geq 15.8$  pg/mL), SOFA score ( $\geq 3.5$ ), and CURB-65 score ( $\geq 0.5$ ), the  
452 simplified RALE score  $\geq 5.5$  (adjusted OR: 18.437; 95% CI: 3.215-105.741;  $p = 0.001$ )  
453 remained independently associated with an increased risk of hospital mortality (Table 4).  
454 Table 4 also shows other factors that were related to hospital mortality.

455

456

457

458

459

460

461

462

463

464

465

466





Simplified RALE score $\geq$ 5.5 <sup>a</sup>	13.000	3.786	44.637	<0.001	18.437	3.215	105.741	0.001
<b>Laboratory investigation</b>								
The 1st-day serum IL-6 level $\geq$ 15.8 pg/mL <sup>a</sup>	2.514	0.927	6.822	0.070	NA	NA	NA	NA
<b>Severity of illness</b>								
SOFA Score $\geq$ 3.5 <sup>a</sup>	6.667	1.707	26.042	0.006	NA	NA	NA	NA
CURB-65 Score $\geq$ 0.5 <sup>a</sup>	8.875	2.835	27.786	<0.001	15.124	3.004	76.148	0.001
Constant					0.062			0.008

<sup>a</sup> The number represents the best cut-off value determined by analysing the receiver operator characteristic curve for each variable.

**Abbreviations:** **AOR**, adjusted odds ratio; **APACHE II**, Acute Physiology and Chronic Health Evaluation II; **CCI**, Charlson Comorbidity Index; **CI**, confidence interval; **CURB-65**, Confusion, Urea  $>7$  mmol/L, Respiratory Rate  $\geq 30$  breaths/min, Blood Pressure  $<90$  mm Hg (Systolic) or  $<60$  mm Hg (Diastolic), Age  $\geq 65$  Years Criteria; **IL-6**, Interleukin 6; **NA**, not available; **OR**, odds ratio; **SOFA**, Sequential Organ Failure Assessment; **RALE**, the Radiographic Assessment of Lung Edema.

470

471

472

473

474

475

476 **DISCUSSION**

477 In the present study, we found that nearly four-fifths of critically ill COVID-19 patients with  
478 the Delta variant died in the hospital (Tables 1 and 2). Upon admission, most patients  
479 exhibited bilateral lung opacities on their CXR, with the highest occurrence of opacity  
480 distribution spanning three to four quadrants of the lungs (Table 2), a high median simplified  
481 RALE score (Table 2), and a low mean PaO<sub>2</sub>/FiO<sub>2</sub> ratio (Table 2). In contrast to the  
482 PaO<sub>2</sub>/FiO<sub>2</sub> ratio, serum IL-6 level, and APACHE II score (S6 Table in S1 File), the simplified  
483 RALE score exhibited a good discriminatory ability in predicting hospital mortality (Fig 1,  
484 S6 Table in S1 File). Similarly, both the SOFA score and CURB-65 score also demonstrated  
485 good discrimination in predicting hospital mortality (Fig 1, S6 Table in S1 File). Notably,  
486 there were no differences between the AUROC curves of the simplified RALE score and  
487 those of the SOFA and CURB-65 score (S7 Table in S1 File). Although the coefficients were  
488 modest, the simplified RALE score correlated with the SOFA and CURB-65 scores (Table  
489 3). Furthermore, the present study revealed a significant association between the simplified  
490 RALE score of  $\geq 5.5$  and an increased risk of hospital mortality (Table 4). Even after  
491 adjusting for confounding factors such as age ( $\geq 60$  years), male gender, CCI score ( $\geq 1.5$ ),  
492 serum IL-6 levels upon admission ( $\geq 15.8$  pg/mL), SOFA score ( $\geq 3.5$ ), and CURB-65 score  
493 ( $\geq 0.5$ ), the simplified RALE score of  $\geq 5.5$  remained independently associated with an  
494 increased risk of hospital mortality (Table 4).

495 In our study, the hospital mortality rate is higher than the rates reported in other Vietnamese  
496 studies conducted in Ho Chi Minh City (52.2%; 263/504)(15) and Binh Duong Province  
497 (64.2%; 97/151)(32), as well as an Indian study (54.6%; 306/560)(31). These disparities may  
498 arise from variations in the inclusion criteria across studies. For example, our study only  
499 included critically ill COVID-19 patients who had CXRs taken upon hospital admission.

500 Moreover, our hospital mortality rate greatly surpasses that reported in a Swedish study  
501 (38.2%; 190/498)(33). The variation observed may stem from differences in the patients,  
502 pathogens, and clinical ability to care for critically ill patients between low- to middle-income  
503 and high-income country settings.(34-37) Additionally, the study centre almost only admitted  
504 critically ill patients with COVID-19 (92.4%, 85/92; S1 Table in S1 File) who encountered  
505 difficulties accessing treatment at lower-level hospitals, with a low rate of intubation (16.7%,  
506 16/96; S1 Table in S1 File) and mechanical ventilation (14.0%, 14/100; S1 Table in S1 File)  
507 during transportation. Transferring critically ill patients with COVID-19 from a local to a  
508 central hospital may result in the worsening of their critical condition. Patient transfers in  
509 Vietnam may occur without intubation, ventilation, PEEP, and other medical  
510 interventions.(38-40) Although data on transfer conditions is limited, a prior survey  
511 highlighted several risk factors associated with increased patient transfers and suboptimal  
512 pre-hospital care quality.(41) Therefore, the cohort of the present study is likely to be  
513 overestimated in the hospital mortality rate.

514 In the early COVID-19 pandemic, the requirement to transfer a patient with COVID-19 to an  
515 ICU mainly depends on their SpO<sub>2</sub>, in addition to concurrent comorbidities.(6) However,  
516 there is a suggestion that this determination could also be made using imaging. Furthermore,  
517 CXRs have also been proposed as a measure for predicting the severity of COVID-19 by  
518 assessing the extent of lung involvement (7-9, 11, 12, 26), thereby offering insights into the  
519 prognosis of the infection. Although data on simple CXR severity scoring systems for  
520 COVID-19 patient mortality is scarce, a Pakistan retrospective study indicates that the initial  
521 simplified RALE score (adjusted OR: 1.278; 95% CI: 1.010–1.617) is identified as an  
522 independent predictor of hospital mortality.(11) Similarly, another Vietnamese retrospective  
523 study also shows that the simplified RALE score (OR: 1.10; 95% CI: 1.04–1.18) is  
524 significantly associated with a higher risk of hospital mortality.(12) These findings align with

525 the present study, which highlighted the good predictive ability of the simplified RALE score  
526 in assessing hospital mortality risk (Fig 1), particularly when the score reaches  $\geq 5.5$  (Table  
527 4). For pinpointing those most at risk of dying among critically ill COVID-19 patients, the  
528 simplified RALE score may be utilized effectively.

529 The present study unveiled that the  $\text{PaO}_2/\text{FiO}_2$  ratio and serum IL-6 level exhibited a poor  
530 discriminatory ability in predicting hospital mortality (S6 Table in S1 File). The reliability of  
531 these measures remains a topic of ongoing debate.(42-51) A Chinese retrospective study  
532 demonstrated that the  $\text{PaO}_2/\text{FiO}_2$  ratio (with an AUROC of 0.865 and a 95% CI of 0.748–  
533 0.941) had excellent discrimination in predicting hospital mortality in COVID-19 patients  
534 requiring intensive care.(42) However, an Italian prospective study revealed a contrasting  
535 result, with the  $\text{PaO}_2/\text{FiO}_2$  ratio (AUROC: 0.688, 95% CI: 0.650–0.846) showing poor  
536 discriminatory ability in predicting hospital mortality.(44) An earlier critique identified a  
537 caution problem with the  $\text{PaO}_2/\text{FiO}_2$  ratio: while  $\text{PaO}_2$  accurately reflects a COVID-19  
538 patient's oxygenation, its reliability diminishes when expressed as a  $\text{PaO}_2/\text{FiO}_2$  ratio.(43) As  
539 a result, inconsistent data may arise regarding the predictive value of this ratio.(42, 44) In  
540 terms of serum IL-6 level, the Chinese study found it had an excellent discriminatory ability  
541 to predict hospital mortality (AUROC: 0.900, 95% CI: 0.791–0.964).(42) However, a meta-  
542 analysis suggested that although serum IL-6 is a useful diagnostic marker for predicting  
543 severe disease, it does not appear to be associated with COVID-19 mortality.(46)  
544 Interestingly, a Belgian retrospective study observed significant differences in serum IL-6  
545 levels between survivors and non-survivors over time, with the maximum serum IL-6 value  
546 emerging as a predictor of ICU mortality in critically ill COVID-19 patients.(47) Thus,  
547 integrating serum IL-6 into the COVID-19 prognosis warrants further exploration.

548 The spectrum of COVID-19 in adults ranges from asymptomatic infection to mild respiratory  
549 tract symptoms to severe pneumonia with ARDS and multi-organ dysfunction. For patients  
550 with a working diagnosis of COVID-19 pneumonia, the crucial steps in management are  
551 defining the severity of the illness and determining the most appropriate site of care.  
552 Clinicians frequently use the CURB-65 severity score due to its straightforwardness.(25) The  
553 present study found that the CURB-65 score exhibited good discrimination in predicting  
554 hospital mortality (Fig 1, S6 Table in S1 File), consistent with the finding from a  
555 comprehensive analysis of 22 predictive models applied to 411 hospitalized adults with  
556 COVID-19, which also highlighted that the CURB-65 score demonstrated good  
557 discriminatory ability in predicting 30-day mortality (AUROC: 0.75, 95% CI: 0.7–0.8)(52).  
558 Several predictive models have been suggested, but none stands out as significantly superior  
559 or precisely predicts the deterioration or mortality in critically ill patients with COVID-  
560 19.(34, 35, 52-56) Although the APACHE IV score is the most up-to-date version, some  
561 centres still use older versions, including the APACHE II score. The present study showed  
562 that the APACHE II score had poor discrimination in predicting hospital mortality in  
563 critically ill COVID-19 patients (S6 Table in S1 File), aligned with the finding of an earlier  
564 published Belgian retrospective study, which also reported a poor discriminatory ability in  
565 predicting hospital mortality using the APACHE II score (AUROC: 0.633).(56) These  
566 findings are supported by previous studies, which revealed that the APACHE II score had a  
567 good prognostic value in acutely ill or surgical patients (24, 57) but did not differentiate  
568 between sterile and infected necrotizing pancreatitis and had a poor predictive value for the  
569 severity of acute pancreatitis at 24 hours (58). However, the present study showed that the  
570 SOFA score demonstrated good discrimination in predicting hospital mortality (Fig 1, S6  
571 Table in S1 File). In a large American cohort of patients with COVID-19 who were without  
572 mechanical ventilation within 24 hours of admission and those without a designation of do-

573 not-resuscitate (DNR) status present at admission, the SOFA score (AUROC: 0.66, 95% CI:  
574 0.65–0.67) exhibited a poor discriminatory ability in predicting hospital mortality.(54) This  
575 variation might be because the illness severity of our patients was worse than those of the  
576 large American cohort (mean SOFA score: 2.77 (SD: 1.91))(54). These findings are  
577 supported by an Iranian prospective study, which reported that the mean of daily SOFA  
578 scores during ICU admission (AUROC: 0.895) had excellent discrimination in predicting  
579 hospital mortality(59).

580 As previously mentioned, the predictive value of the test results and predictive models we  
581 discussed for assessing critically ill patients with COVID-19 remains uncertain, and the  
582 optimal utilization of these diagnostic markers and models remains unknown. However, the  
583 present study shows that the simplified RALE score, SOFA score, and CURB-65 score  
584 demonstrated good discrimination in predicting hospital mortality (Fig 1, S6 Table in S1  
585 File), with no differences between their AUROC curves (S7 Table in S1 File). Although the  
586 coefficients were modest, the simplified RALE score correlated with the SOFA and CURB-  
587 65 scores (Table 3, S8 Table in S1 File). These findings align with previously published  
588 studies, which report that the CXR scoring system is suggested as a tool to predict the  
589 severity of COVID-19 by assessing lung involvement(7-9, 11, 12). Thus, to quantify the  
590 severity of COVID-19 pneumonia, the simplified RALE score may also be utilized  
591 effectively.

592 The present study has certain limitations. *Firstly*, it was conducted at a single centre in Ho  
593 Chi Minh City, Vietnam, focusing on a highly selected group of cases. The study site was  
594 urgently established in Ho Chi Minh City in response to the Delta variant epidemic, which  
595 posed significant challenges for medical providers dealing with a large influx of COVID-19  
596 patients. Additionally, all COVID-19 patients were transferred from various hospitals within

597 the Ho Chi Minh City area, and the treatments they received before admission influenced  
598 their disease severity upon enrolment. As a result, these elements hinder the seamless  
599 integration of pre-hospital and hospital treatment procedures, as well as the collection of  
600 clinical data for surveillance, quality enhancement, and research purposes. Additionally, they  
601 introduce an implicit selection bias and incomplete patient inclusion in the study database,  
602 which could potentially result in an overestimation of the mortality rate. *Secondly*, we  
603 conducted the present study during the Delta variant epidemic in Vietnam; however, no  
604 included patients with COVID-19 underwent genomic analysis to confirm infection with a  
605 SARS-CoV-2 mutant virus strain. However, according to sequencing data at the time of the  
606 study period in Ho Chi Minh City, COVID-19 was almost entirely caused by one lineage of  
607 the Delta variant (AY.57).(60) In that sense, we evaluated a relatively homogeneous patient  
608 population in virologically. *Finally*, although the sample size was large enough, the  
609 confidence interval was wide ( $\pm 8.02\%$ ), which might influence the normal distribution of the  
610 collected sample. Further studies with larger sample sizes might be needed to consolidate the  
611 conclusions.

612

## 613 **CONCLUSIONS**

614 This study investigated a highly selected cohort of critically ill COVID-19 patients with the  
615 Delta variant, a high simplified RALE score, and a high mortality rate presented to an  
616 Intensive Care Centre for the Treatment of Critically Ill Patients with COVID-19 in Ho Chi  
617 Minh City, Vietnam. Beyond its ability to quantify severity and predict hospital mortality, the  
618 simplified RALE score also emerged as an independent predictor of hospital mortality. For  
619 pinpointing those most at risk of progressing and dying among critically ill COVID-19  
620 patients, the simplified RALE score can be utilized effectively.

621

**622 Acknowledgements**

623 We are grateful to the special task teams from the Bach Mai Hospital and Vietnam's Ministry  
624 of Health and to all the healthcare heroes across the country who helped Ho Chi Minh City  
625 during the third wave of the COVID-19 pandemic in Vietnam. We also appreciate the support  
626 and statistical advice from the staff of the Faculty of Public Health at the Thai Binh  
627 University of Medicine and Pharmacy. Finally, we thank Miss Truc-Cam Nguyen from  
628 Stanford University, Stanford, California, the United States of America, and Miss Mai  
629 Phuong Nguyen from the Hotchkiss School, Lakeville, Connecticut, the United States of  
630 America, for their support of our manuscript.

631

**632 References**

- 633 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from  
634 Patients with Pneumonia in China, 2019. *The New England journal of medicine*.  
635 2020;382(8):727-33.
- 636 2. World Health Organization (WHO). Statement on the second meeting of the  
637 International Health Regulations (2005) Emergency Committee regarding the outbreak of  
638 novel coronavirus (2019-nCoV). Geneva, Switzerland: WHO; 2020 [updated January 30,  
639 2020; cited 2024 February 25]. Available from: [https://www.who.int/news-room/detail/30-  
640 01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-  
641 emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)).



- 642 3. World Health Organization (WHO). WHO Director-General's opening remarks at the  
643 media briefing on COVID-19 - 11 March 2020. Geneva, Switzerland: WHO; 2020 [updated  
644 March 11, 2020; cited 2024 February 25]. Available from:  
645 [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
646 [media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020).
- 647 4. Number of COVID-19 cases reported to WHO (cumulative total) [Internet]. WHO.  
648 2024 [cited February 22, 2024]. Available from:  
649 <https://data.who.int/dashboards/covid19/cases>.
- 650 5. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers.  
651 International journal of infectious diseases : IJID : official publication of the International  
652 Society for Infectious Diseases. 2020;95:304-7.
- 653 6. Borghesi A, Zigliani A, Masciullo R, Golemi S, Maculotti P, Farina D, et al.  
654 Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783  
655 Italian patients. La Radiologia medica. 2020;125(5):461-4.
- 656 7. Monaco CG, Zaottini F, Schiaffino S, Villa A, Della Pepa G, Carbonaro LA, et al.  
657 Chest x-ray severity score in COVID-19 patients on emergency department admission: a two-  
658 centre study. European radiology experimental. 2020;4(1):68.
- 659 8. Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray  
660 scoring system for quantifying and monitoring disease progression. La Radiologia medica.  
661 2020;125(5):509-13.
- 662 9. Wong HYF, Lam HYS, Fong AH-T, Leung ST, Chin TW-Y, Lo CSY, et al.  
663 Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-  
664 19. Radiology. 2020;296(2):E72-E8.

- 665 10. Warren MA, Zhao Z, Koyama T, Bastarache JA, Shaver CM, Semler MW, et al.  
666 Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes  
667 in ARDS. *Thorax*. 2018;73(9):840-6.
- 668 11. Kaleemi R, Hilal K, Arshad A, Martins RS, Nankani A, Tu H, et al. The association  
669 of chest radiographic findings and severity scoring with clinical outcomes in patients with  
670 COVID-19 presenting to the emergency department of a tertiary care hospital in Pakistan.  
671 *PloS one*. 2021;16(1):e0244886.
- 672 12. Hoang SV, Nguyen KM, Huynh TM, Huynh KLA, Nguyen PH, Tran HPN. Chest X-  
673 ray Severity Score as a Putative Predictor of Clinical Outcome in Hospitalized Patients: An  
674 Experience From a Vietnamese COVID-19 Field Hospital. *Cureus*. 2022;14(3):e23323.
- 675 13. Takashima K, Wada K, Tra TT, Smith DR. A review of Vietnam's healthcare reform  
676 through the Direction of Healthcare Activities (DOHA). *Environmental health and preventive  
677 medicine*. 2017;22(1):74.
- 678 14. World Health Organization. COVID-19 Situation reports in Viet Nam Geneva,  
679 Switzerland: The World Health Organization; 2021 [updated June 7, 2023; cited 2024  
680 February 14]. Available from: [https://www.who.int/vietnam/emergencies/coronavirus-  
681 disease-\(covid-19\)-in-viet-nam/covid-19-situation-reports-in-viet-nam/](https://www.who.int/vietnam/emergencies/coronavirus-disease-(covid-19)-in-viet-nam/covid-19-situation-reports-in-viet-nam/).
- 682 15. Do TV, Manabe T, Vu GV, Nong VM, Fujikura Y, Phan D, et al. Clinical  
683 characteristics and mortality risk among critically ill patients with COVID-19 owing to the  
684 B.1.617.2 (Delta) variant in Vietnam: A retrospective observational study. *PloS one*.  
685 2023;18(1):e0279713.
- 686 16. World Health Organization (WHO). Public health surveillance for COVID-19:  
687 interim guidance. Geneva, Switzerland: WHO; 2020 [updated July 22, 2022; cited 2024

688 February 14]. Available from: [https://www.who.int/publications/i/item/who-2019-nCoV-](https://www.who.int/publications/i/item/who-2019-nCoV-surveillanceguidance-2020.8/)  
689 [surveillanceguidance-2020.8/](https://www.who.int/publications/i/item/who-2019-nCoV-surveillanceguidance-2020.8/).

690 17. Vietnam Ministry of Health. Decision 4689/QĐ-BYT 2021 on the Guidance on  
691 COVID-19 diagnosis and treatment. In: Department of Medical Service Administration,  
692 editor. 7th ed. Hanoi, Vietnam: Ministry of Health,; 2021.

693 18. Patel A, Jernigan DB. Initial Public Health Response and Interim Clinical Guidance  
694 for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4,  
695 2020. MMWR Morbidity and mortality weekly report. 2020;69(5):140-6.

696 19. NIH COVID-19 Treatment Panel. Coronavirus Disease 2019 (COVID-19) Treatment  
697 Guidelines Maryland, United States of America: National Institutes of Health; 2020 [updated  
698 December 20, 2023; cited 2024 February 14]. Available from:  
699 <https://www.covid19treatmentguidelines.nih.gov/>.

700 20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying  
701 prognostic comorbidity in longitudinal studies: development and validation. Journal of  
702 chronic diseases. 1987;40(5):373-83.

703 21. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and  
704 validating the Charlson comorbidity index and score for risk adjustment in hospital discharge  
705 abstracts using data from 6 countries. American journal of epidemiology. 2011;173(6):676-  
706 82.

707 22. Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O, et al. Validity of  
708 Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights  
709 from the nationwide AMIS Plus registry 2002-2012. Heart (British Cardiac Society).  
710 2014;100(4):288-94.

- 711 23. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The  
712 SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure.  
713 On behalf of the Working Group on Sepsis-Related Problems of the European Society of  
714 Intensive Care Medicine. *Intensive care medicine*. 1996;22(7):707-10.
- 715 24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of  
716 disease classification system. *Critical care medicine*. 1985;13(10):818-29.
- 717 25. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al.  
718 Defining community acquired pneumonia severity on presentation to hospital: an  
719 international derivation and validation study. *Thorax*. 2003;58(5):377-82.
- 720 26. American College of Radiology (ACR). ACR Recommendations for the use of Chest  
721 Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection Virginia,  
722 United States: American College of Radiology; 2020 [updated March 22, 2020; cited 2024  
723 March 11]. Available from: [https://www.acr.org/Advocacy-and-Economics/ACR-Position-  
724 Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-  
725 Infection](https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection).
- 726 27. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al.  
727 Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016  
728 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American  
729 Thoracic Society. *Clinical infectious diseases : an official publication of the Infectious  
730 Diseases Society of America*. 2016;63(5):e61-e111.
- 731 28. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson  
732 ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. *Jama*.  
733 2012;307(23):2526-33.

- 734 29. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, et al. The  
735 Berlin definition of ARDS: an expanded rationale, justification, and supplementary material.  
736 *Intensive care medicine*. 2012;38(10):1573-82.
- 737 30. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et  
738 al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).  
739 *Jama*. 2016;315(8):801-10.
- 740 31. Mahendra M, Nuchin A, Kumar R, Shreedhar S, Mahesh PA. Predictors of mortality  
741 in patients with severe COVID-19 pneumonia - a retrospective study. 2021;89(2):135-44.
- 742 32. Duong-Quy S, Huynh-Truong-Anh D, Nguyen-Thi-Kim T, Nguyen-Quang T, Tran-  
743 Ngoc-Anh T, Nguyen-Van-Hoai N, et al. Predictive Factors of Mortality in Patients with  
744 Severe COVID-19 Treated in the Intensive Care Unit: A Single-Center Study in Vietnam.  
745 *Pulmonary therapy*. 2023;9(3):377-94.
- 746 33. Didriksson I, Leffler M, Spångfors M, Lindberg S, Reepalu A, Nilsson A, et al.  
747 Intensive care unit burden is associated with increased mortality in critically ill COVID-19  
748 patients. *Acta anaesthesiologica Scandinavica*. 2023;67(3):329-38.
- 749 34. Do SN, Dao CX, Nguyen TA, Nguyen MH, Pham DT, Nguyen NT, et al. Sequential  
750 Organ Failure Assessment (SOFA) Score for predicting mortality in patients with sepsis in  
751 Vietnamese intensive care units: a multicentre, cross-sectional study. *BMJ open*.  
752 2023;13(3):e064870.
- 753 35. Do SN, Luong CQ, Nguyen MH, Pham DT, Nguyen NT, Huynh DQ, et al. Predictive  
754 validity of the quick Sequential Organ Failure Assessment (qSOFA) score for the mortality in  
755 patients with sepsis in Vietnamese intensive care units. *PloS one*. 2022;17(10):e0275739.

- 756 36. Do SN, Luong CQ, Pham DT, Nguyen MH, Nguyen NT, Huynh DQ, et al. Factors  
757 relating to mortality in septic patients in Vietnamese intensive care units from a subgroup  
758 analysis of MOSAICS II study. *Scientific reports*. 2021;11(1):18924.
- 759 37. Schultz MJ, Dunser MW, Dondorp AM, Adhikari NK, Iyer S, Kwizera A, et al.  
760 Current challenges in the management of sepsis in ICUs in resource-poor settings and  
761 suggestions for the future. *Intensive care medicine*. 2017;43(5):612-24.
- 762 38. Chinh LQ, Manabe T, Son DN, Chi NV, Fujikura Y, Binh NG, et al. Clinical  
763 epidemiology and mortality on patients with acute respiratory distress syndrome (ARDS) in  
764 Vietnam. *PloS one*. 2019;14(8):e0221114-e.
- 765 39. Do SN, Luong CQ, Pham DT, Nguyen CV, Ton TT, Pham TTN, et al. Survival after  
766 out-of-hospital cardiac arrest, Viet Nam: multicentre prospective cohort study. *Bulletin of the*  
767 *World Health Organization*. 2021;99(1):50-61.
- 768 40. Do SN, Luong CQ, Pham DT, Nguyen MH, Ton TT, Hoang QTA, et al. Survival after  
769 traumatic out-of-hospital cardiac arrest in Vietnam: a multicenter prospective cohort study.  
770 *BMC emergency medicine*. 2021;21(1):148.
- 771 41. Nielsen K, Mock C, Joshipura M, Rubiano AM, Zakariah A, Rivara F. Assessment of  
772 the status of prehospital care in 13 low- and middle-income countries. *Prehospital emergency*  
773 *care : official journal of the National Association of EMS Physicians and the National*  
774 *Association of State EMS Directors*. 2012;16(3):381-9.
- 775 42. Gu Y, Wang D, Chen C, Lu W, Liu H, Lv T, et al. PaO<sub>2</sub>/FiO<sub>2</sub> and IL-6 are risk  
776 factors of mortality for intensive care COVID-19 patients. *Scientific reports*.  
777 2021;11(1):7334.

- 778 43. Tobin MJ, Jubran A, Laghi F. P (aO<sub>2</sub>) /F (IO<sub>2</sub>) ratio: the mismeasure of  
779 oxygenation in COVID-19. *The European respiratory journal*. 2021;57(3).
- 780 44. Prediletto I, D'Antoni L, Carbonara P, Daniele F, Dongilli R, Flore R, et al.  
781 Standardizing PaO<sub>2</sub> for PaCO<sub>2</sub> in P/F ratio predicts in-hospital mortality in acute respiratory  
782 failure due to Covid-19: A pilot prospective study. *European journal of internal medicine*.  
783 2021;92:48-54.
- 784 45. Laguna-Goya R, Utrero-Rico A, Talayero P, Lasa-Lazaro M, Ramirez-Fernandez A,  
785 Naranjo L, et al. IL-6-based mortality risk model for hospitalized patients with COVID-19.  
786 *The Journal of allergy and clinical immunology*. 2020;146(4):799-807.e9.
- 787 46. Liu X, Wang H, Shi S, Xiao J. Association between IL-6 and severe disease and  
788 mortality in COVID-19 disease: a systematic review and meta-analysis. 2022;98(1165):871-  
789 9.
- 790 47. Gorham J, Moreau A, Corazza F, Peluso L, Ponthieux F, Talamonti M, et al.  
791 Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis. *PloS one*.  
792 2021;15(12):e0244628.
- 793 48. Nikkhoo B, Mohammadi M, Hasani S, Sigari N, Borhani A, Ramezani C, et al.  
794 Elevated interleukin (IL)-6 as a predictor of disease severity among Covid-19 patients: a  
795 prospective cohort study. *BMC infectious diseases*. 2023;23(1):311.
- 796 49. Hardavella G, Marinou I, Keramida E, Bellou E, Mavrea S, Georgakopoulou E, et al.  
797 Can IL-6 serve as a reliable biomarker of clinical outcome in COVID19 pneumonia?  
798 *European Respiratory Journal*. 2022;60(suppl 66):4140.

- 799 50. Jamoussi A, Messaoud L, Jarraya F, Rachdi E, Ben Mrad N, Yaalaoui S, et al.  
800 Interleukin6 prediction of mortality in critically ill COVID19 patients: A prospective  
801 observational cohort study. *PloS one*. 2023;18(3):e0279935.
- 802 51. Sivakorn C, Dechsanga J, Jamjumrus L, Boonnak K, Schultz MJ, Dondorp AM, et al.  
803 High Mobility Group Box 1 and Interleukin 6 at Intensive Care Unit Admission as  
804 Biomarkers in Critically Ill COVID-19 Patients. *The American journal of tropical medicine*  
805 *and hygiene*. 2021;105(1):73-80.
- 806 52. Gupta RK, Marks M, Samuels THA, Luintel A, Rampling T, Chowdhury H, et al.  
807 Systematic evaluation and external validation of 22 prognostic models among hospitalised  
808 adults with COVID-19: an observational cohort study. *European Respiratory Journal*.  
809 2020;56(6):2003498.
- 810 53. Raschke RA, Agarwal S, Rangan P, Heise CW, Curry SC. Discriminant Accuracy of  
811 the SOFA Score for Determining the Probable Mortality of Patients With COVID-19  
812 Pneumonia Requiring Mechanical Ventilation. *Jama*. 2021;325(14):1469-70.
- 813 54. Keller MB, Wang J, Nason M, Warner S, Follmann D, Kadri SS. Preintubation  
814 Sequential Organ Failure Assessment Score for Predicting COVID-19 Mortality: External  
815 Validation Using Electronic Health Record From 86 U.S. Healthcare Systems to Appraise  
816 Current Ventilator Triage Algorithms. *Critical care medicine*. 2022;50(7):1051-62.
- 817 55. Zou X, Li S, Fang M, Hu M, Bian Y, Ling J, et al. Acute Physiology and Chronic  
818 Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus  
819 Disease 2019. *Critical care medicine*. 2020;48(8):e657-e65.



- 820 56. Vandenbrande J, Verbrugge L, Bruckers L, Geebelen L, Geerts E, Callebaut I, et al.  
821 Validation of the Acute Physiology and Chronic Health Evaluation (APACHE) II and IV  
822 Score in COVID-19 Patients. *Critical care research and practice*. 2021;2021:5443083.
- 823 57. Capuzzo M, Valpondi V, Sgarbi A, Bortolazzi S, Pavoni V, Gilli G, et al. Validation  
824 of severity scoring systems SAPS II and APACHE II in a single-center population. *Intensive  
825 care medicine*. 2000;26(12):1779-85.
- 826 58. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. *The American  
827 journal of gastroenterology*. 2006;101(10):2379-400.
- 828 59. Beigmohammadi MT, Amoozadeh L, Rezaei Motlagh F, Rahimi M, Maghsoudloo M,  
829 Jafarnejad B, et al. Mortality Predictive Value of APACHE II and SOFA Scores in COVID-  
830 19 Patients in the Intensive Care Unit. *Canadian Respiratory Journal*. 2022;2022:5129314.
- 831 60. Hoang TH, Vu GM, Tran MH, Tran TTH, Le QD, Tran KV, et al. Investigation of  
832 target sequencing of SARS-CoV-2 and immunogenic GWAS profiling in host cells of  
833 COVID-19 in Vietnam. *BMC infectious diseases*. 2022;22(1):558.

834

**835 Supporting information**

836 S1 File. Supplementary Results

# ROC Curve




Figure 1